RxDoctor Payments Data

Corey Burr, OD

Optometrist · Shallotte, NCNPI 1447865357

Payments from drug & device makers

$3,945in general payments, 2019–2025

Across 110 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$958
  • Coopervision Inc.$906
  • Sun Pharmaceutical Industries Inc.$583
  • Alcon$488
  • Johnson & Johnson Vision Care, Inc.$345
  • Apellis Pharmaceuticals, Inc.$124
  • plus $541 from 9 others

What the payments were for

  • Food & beverage$3,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,945 in reported general payments places this provider in the 85th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$234,689
Medicare patients
1,220
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$67,598
TyrvayaVarenicline Tartrate43$34,073
XiidraLifitegrast13$18,333
LumiganBimatoprost20$14,669
CequaCyclosporine17$14,247
Cyclosporine14$10,269
MieboPerfluorohexyloctane/Pf11$8,081
Restasis MultidoseCyclosporine11$6,798
Alphagan PBrimonidine Tartrate15$5,436
Latanoprost247$3,984
Prednisolone Acetate52$2,364
Travoprost16$2,197
Brimonidine Tartrate34$1,135
Timolol Maleate91$1,028
Dorzolamide Hcl48$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Alphagan P$96$94,50192 claims
Oyster Point Pharma, Inc.Tyrvaya$112$34,07343 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$958$26,41424 claims
Sun Pharmaceutical Industries Inc.Cequa$583$14,24717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Shallotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →